ĐÁNH GIÁ MỘT SỐ TÁC DỤNG KHÔNG MONG MUỐN CỦA PHÁC ĐỒ XELOX TRONG ĐIỀU TRỊ BỆNH NHÂN UNG THƯ DẠ DÀY GIAI ĐOẠN MUỘN TẠI BỆNH VIỆN K

Abstract

Objective: Evaluate some side effects of the XELOX regimen in patients with late-stage gastric cancer. Patients and methods: Cross-sectional descriptive study on 52 patients with a confirmed diagnosis of late-stage gastric cancer, no longer amenable to radical surgery, treated with the XELOX regimen at the hospital, at Vietnam National Cancer Hospital from June 2016 to March 2020. Results: The majority of patients in the study were treated with doses ranging from 85% to 100%, accounting for 96,2% (n=50), on average each patient was treated with a value 7,06 cycles. Leukopenia was found in 44,2% of patients and only in patients with grade 1 and 2 leukopenia. Leukopenia accounted for 51,9% of patients, mainly grade 1-2 leukopenia and grade 3 leukopenia. accounting for 9,6% of patients. Anemia accounts for 55,7% of patients. Thrombocytopenia is less common in 28,8% of patients. Kidney toxicity accounts for 9,6% of patients. Liver toxicity: accounts for 27%-40,4% of patients, and only occurs in patients with grade 1 and grade 2 liver enzyme elevations. Vomiting and nausea occur in 38,4% of cases, diarrhea accounts for 23,1, and fatigue accounts for 40,3%, but most of it is at a mild level. Conclusion: In general, patients with late-stage gastric cancer tolerated the XELOX regimen well, most of the unwanted effects on the hematopoietic system, liver, and kidney, and clinically were only at levels 1-2.